Details for Patent: 8,623,883

Which drugs does patent 8,623,883 protect, and when does it expire?

Patent 8,623,883 protects VIZIMPRO and is included in one NDA.

This patent has fifty-seven patent family members in forty-six countries.

Summary for Patent: 8,623,883

Title:	4-phenylamino-quinazolin-6-yl-amides
Abstract:	This invention provides quinazoline compounds of the formula: ##STR00001## wherein: R.sub.1 is halo; R.sub.2 is H or halo; R.sub.3 is a) C.sub.1-C.sub.3 alkyl, optionally substituted by halo; or b) --(CH.sub.2).sub.n-morpholino, --(CH.sub.2).sub.n-piperidine, --(CH.sub.2).sub.n-piperazine, --(CH.sub.2).sub.n-piperazine-N(C.sub.1-C.sub.3 alkyl), --(CH.sub.2).sub.n-pyrrolidine, or --(CH.sub.2).sub.n-imidazole; n is 1 to 4; R.sub.4 is --(CH.sub.2).sub.m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C.sub.1-C.sub.3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH.sub.2, NH(C.sub.1-C.sub.3 alkyl) or N(C.sub.1-C.sub.3 alkyl).sub.2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.
Inventor(s):	Fakhoury; Stephen Alan (Fishers, IN), Lee; Helen Tsenwhei (Ann Arbor, MI), Reed; Jessica Elizabeth (Ann Arbor, MI), Schlosser; Kevin Matthew (North Wales, PA), Sexton; Karen Elaine (Kent, GB), Tecle; Haile (Ann Arbor, MI), Winters; Roy Thomas (Pinckney, MI)
Assignee:	Warner-Lambert Company LLC (Morris Plains, NJ)
Application Number:	13/914,410
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,623,883

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-001	Sep 27, 2018		RX	Yes	No						FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-002	Sep 27, 2018		RX	Yes	No						FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-003	Sep 27, 2018		RX	Yes	Yes						FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

International Family Members for US Patent 8,623,883

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1746999		301004	Netherlands
European Patent Office	1746999		PA2019016	Lithuania
European Patent Office	1746999		122019000080	Germany